For help on how to get the results you want, see our search tips.
268 results
Medicine
Maximum residue limits Remove Maximum residue limits filter
Withdrawn applications Remove Withdrawn applications filter
Paediatric investigation plans Remove Paediatric investigation plans filter
PIP compliance check
Yes Remove Yes filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Nulibry, Fosdenopterin (ORGN001)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Other
PIP number: EMEA-001491-PIP01-13-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for infusion
Decision date: 13/04/2022, Last updated: 19/04/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Halaven, Eribulin
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001261-PIP01-11-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for injection
Decision date: 06/12/2021, Last updated: 16/03/2023, Compliance check: V, 25/02/2022 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tamiflu, Oseltamivir (phosphate)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000365-PIP01-08-M12, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Powder for oral suspension
Decision date: 25/06/2021, Last updated: 13/03/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Brilique, Ticagrelor
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Cardiovascular diseases; Haematology-Hemostaseology
PIP number: EMEA-000480-PIP01-08-M14, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Orodispersible tablet, Tablet
Decision date: 09/04/2021, Last updated: 13/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Eylea, aflibercept
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Ophthalmology
PIP number: EMEA-000236-PIP05-18, Route(s) of administration: Intravitreal use, Pharmaceutical form(s): Solution for injection
Decision date: 04/04/2019, Last updated: 13/03/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000380-PIP01-08-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder for solution for injection, Solution for injection
Decision date: 01/12/2017, Last updated: 13/03/2023, Compliance check: V, 20/04/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cosentyx, Secukinumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-000380-PIP02-09-M04, Route(s) of administration: Subcutaneous use, Intravenous use, Pharmaceutical form(s): Powder for solution for injection or infusion, Solution for injection
Decision date: 07/12/2018, Last updated: 13/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tivicay, Dolutegravir (DTG)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000409-PIP01-08-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Age appropriate formulation for oral use, Film-coated tablet
Decision date: 09/07/2021, Last updated: 13/03/2023, Compliance check: V, 15/10/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Elonva, corifollitropin alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: EMEA-000306-PIP01-08-M04, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 17/04/2019, Last updated: 13/03/2023, Compliance check: V, 29/01/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Afstyla, lonoctocog alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001215-PIP01-11-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 10/09/2019, Last updated: 10/03/2023, Compliance check: V, 10/09/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): cerliponase alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-001362-PIP01-12-M03, Route(s) of administration: Intracerebral use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 05/09/2016, Last updated: 10/03/2023, Compliance check: V, 26/02/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Turoctocog alfa pegol
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001174-PIP02-12-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 07/06/2017, Last updated: 10/03/2023, Compliance check: V, 23/07/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Revestive, teduglutide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-000482-PIP01-08-M06, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 01/12/2020, Last updated: 10/03/2023, Compliance check: V, 26/03/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): citric acid (as citric acid anhydrous), macrogol 4000, potassium chloride, simeticone, sodium chloride, sodium citrate, sodium sulfate (as sodium sulfate anhydrous)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001356-PIP02-12-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Powder for oral suspension
Decision date: 14/04/2021, Last updated: 10/03/2023, Compliance check: V, 17/12/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001407-PIP01-12-M03, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 05/11/2020, Last updated: 10/03/2023, Compliance check: V, 21/01/2022 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Idelvion, albutrepenonacog alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001107-PIP01-10-M04, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for infusion, Powder and solvent for solution for injection
Decision date: 29/01/2020, Last updated: 10/03/2023, Compliance check: X, 21/01/2022 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Human-cell-line recombinant human factor VIII (human-cl rhFVIII), Human Coagulation Factor VIII (rDNA)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001024-PIP01-10-M02, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 06/01/2020, Last updated: 10/03/2023, Compliance check: V, 26/03/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Zerbaxa, Ceftolozane, tazobactam
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001142-PIP01-11-M04, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 13/11/2020, Last updated: 10/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cotellic, Cobimetinib
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001425-PIP01-13-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral formulation
Decision date: 17/03/2021, Last updated: 10/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Lamzede, velmanase alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: EMEA-001056-PIP02-12-M01, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for injection
Decision date: 23/10/2020, Last updated: 10/03/2023, Compliance check: V, 23/04/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Iblias, octocog alfa
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001064-PIP01-10-M03, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 16/03/2018, Last updated: 10/03/2023, Compliance check: V, 23/07/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tecfidera, dimethyl fumarate
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000832-PIP01-10-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 15/05/2020, Last updated: 10/03/2023, Compliance check: V, 14/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Trecondi, Treosulfan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation; Oncology
PIP number: EMEA-000883-PIP01-10-M05, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution
Decision date: 09/09/2020, Last updated: 10/03/2023, Compliance check: V, 25/03/2022 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Adcetris, Brentuximab vedotin
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000980-PIP01-10-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion
Decision date: 28/01/2021, Last updated: 10/03/2023, Compliance check: V, 25/06/2021 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Bydureon, exenatide
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: EMEA-000689-PIP01-09-M11, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection, Powder and solvent for prolonged-release suspension for injection, Solution for injection in pre-filled injector
Decision date: 18/02/2021, Last updated: 10/03/2023, Compliance check: V, 21/05/2021